Voyager Therapeutics (NASDAQ:VYGR) Issues Earnings Results, Misses Estimates By $0.24 EPS

Voyager Therapeutics (NASDAQ:VYGR) released its earnings results on Tuesday. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.24), Zacks reports. The company had revenue of $4.39 million for the quarter, compared to analyst estimates of $16.58 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same period in the previous year, the business posted $1.25 EPS.

Voyager Therapeutics Stock Performance

Shares of NASDAQ:VYGR opened at $3.97 on Wednesday. Voyager Therapeutics has a 52-week low of $3.75 and a 52-week high of $10.66. The stock has a 50 day moving average price of $4.98 and a 200-day moving average price of $5.89. The firm has a market capitalization of $216.87 million, a P/E ratio of 5.59 and a beta of 0.99.

Insiders Place Their Bets

In other news, COO Robin Swartz sold 6,500 shares of the stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $5.65, for a total transaction of $36,725.00. Following the completion of the transaction, the chief operating officer now directly owns 112,328 shares in the company, valued at approximately $634,653.20. This represents a 5.47 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last ninety days, insiders have sold 10,778 shares of company stock worth $58,548. Company insiders own 4.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on VYGR. StockNews.com lowered Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Citigroup assumed coverage on shares of Voyager Therapeutics in a research note on Monday, December 2nd. They issued a “buy” rating and a $12.00 target price for the company. Cantor Fitzgerald assumed coverage on shares of Voyager Therapeutics in a research note on Friday, January 10th. They set an “overweight” rating and a $5.73 price target for the company. Wedbush restated an “outperform” rating and issued a $9.00 price target (down from $11.00) on shares of Voyager Therapeutics in a report on Tuesday, February 11th. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $14.00 price objective on shares of Voyager Therapeutics in a report on Thursday, November 14th. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Voyager Therapeutics presently has an average rating of “Buy” and an average target price of $15.72.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.